the aid library

LIST OPTIONS

Filter

2828

Download (108)

View PDF (143)

Revised guidelines for Home Isolation of mild /asymptomatic COVID-19 cases

Ministry of Health& Family Welfare, Goverment of India (2021) CC

28th April 2021

Download (186)

View PDF (145)

COVID-19 Treatment Guidelines

National Department of Health, South Africa (2022) CC

Updated Treatment Guidelines

Download (88)

View PDF (132)

The prolongation of the health crisis and its impact on health, the economy and social development

Pan American Health Organisation PAHO (2021) C_WHO

External Link

The neglected zoonoses—the case for integrated control and advocacy

Welburn S. C., Beange I. et al (2015) C2

Clinical Microbiology and Infection Volume 21, Issue 5, May 2015, Pages 433-443; The neglected zoonotic diseases (NZDs) have been all but eradicated in wealthier countries, but remain major causes of ill-health and mortality across Africa, Asia, and Latin America. This neglect is, in part, a conse... more

Download (128)

View PDF (201)

National Guidelines for the Management of Viral Hepatitis

Spearman, CWN; MW Sonderup, Y Pillay et al. National Department of Health South Africa (2020) CC

Viral hepatitis is defined as inflammation of the liver cells due to viral infection. The burden of liver disease in South Africa is mostly underestimated as viral hepatitis, in particular chronic infection, is a silent and neglected cause of morbidity and mortality. However, the burden of disease i... more

Download (142)

View PDF (161)

Indicators and questions for monitoring progress on the 2021 Political Declaration on HIV and AIDS — Global AIDS Monitoring 2023

UNAIDS (2022) C_WHO

The indicators and questions in this document are designed for use by national AIDS programmes and partners to assess the state of a country’s HIV and AIDS response, and to measure progress towards achieving national HIV targets. Countries are encouraged to integrate these indicators and questions... more

External Link

Surveillance, prevention and control of leishmaniases in the European Union and its neighbouring countries

European Centre for disease prevention and control (ECDC) European Centre for disease prevention and control (ECDC) (2022) C_CDC

This technical report presents the epidemiology of human and animal leishmaniases in the EU and its neighbouring countries and concludes that the disease remains widespread and underreported in many countries of southern Europe, northern Africa, and the Middle East and that there is a need to improv... more

Download (193)

View PDF (241)

Interregional meeting on leishmaniasis among neighbouring endemic countries in the Eastern Mediterranean, African and European regions

World Health Organization WHO (2019) C_WHO

An interregional meeting on leishmaniasis among neighbouring endemic countries in the Eastern Mediterranean, African and European regions was organized by the World Health Organization (WHO) Regional Office for the Eastern Mediterranean in Amman, Jordan, from 23 to 25 September 2018. The meeting w... more

Download (284)

View PDF (380)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (377)

View PDF (867)

Rapid Communication: Key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB)
recommended

World Health Organization WHO (2018) C_WHO

The first important change is a new priority ranking of the available medicines for MDR-TB treatment, based on a careful balance between expected benefits and harms. Treatment success for MDR-TB is currently low in many countries. This could be increased by improving access to the highest-ranked med... more

Download (594)

View PDF (1236)

Annual Report NACO 2013 - 14

NACO, Department of AIDS Control (2013)

Department of AIDS Control Ministry of Health & Family Welfare

Download (619)

View PDF (1021)

National Blood Policy

NACO, NBTC (2007)

Download (343)

View PDF (722)

Operational Guidelines on Community Care Centres

National AIDSControl (NACO), Government of India; Ministry of Health and Family Welfare (2007) C1

Download (270)

View PDF (224)

Operational Guidelines For Community Care Centres

National AIDS Control Organisation, Ministry of Health &; Family Welfare , Government of India, (2007)

Download (628)

View PDF (1241)

National Policy on Infant and Young Child Feeding in Nigeria

Federal Ministry of Health, Nigeria (2010) C1

Download (814)

View PDF (1179)

Lesotho: National Tuberculosis Programme

Minister of Health & Social Welfare (MoHSW), Kingdom of Lesotho (2016) C2

Policy and Manual

Download (2743)

View PDF (1210)

Helping Mothers Survive. Bleeding after Birth. Provider's Guide

Jhpiego; UNFPA; International Confideration of Midwives; et al. Jhpiego; UNFPA; International Confideration of Midwives (2013) CC

BAB training in prevention and management of postpartum hemorrhage increased knowledge and confidence among skilled and semiskilled birth attendants. Further studies are needed to determine the impact of this training on skills retention and clinical outcomes following postpartum hemorrhage, after b... more

Rapid Communication: Key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB) recommended

Rapid Communication: Key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB)
recommended